{"id":9724,"date":"2025-05-06T10:10:25","date_gmt":"2025-05-06T08:10:25","guid":{"rendered":"https:\/\/www.qualipharmagroup.com\/?p=9724"},"modified":"2025-09-03T12:05:53","modified_gmt":"2025-09-03T10:05:53","slug":"nis2-and-the-challenge-of-turning-risk-into-opportunity","status":"publish","type":"post","link":"https:\/\/www.qualipharmagroup.com\/en\/blog\/nis2-and-the-challenge-of-turning-risk-into-opportunity\/","title":{"rendered":"NIS2 and the Challenge of Turning Risk into Opportunity"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"9724\" class=\"elementor elementor-9724\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2a2417f e-flex e-con-boxed e-con e-parent\" data-id=\"2a2417f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-e6ee181 elementor-widget elementor-widget-text-editor\" data-id=\"e6ee181\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p class=\"p1\">You wouldn\u2019t believe how many times, when trying to conduct a Risk Analysis in an organization, we\u2019ve heard things like:\u00a0<i>\u201cIf we only think about the bad stuff, we\u2019ll never get anything done,\u201d\u00a0<\/i><i><\/i><i>\u201cThere\u2019s no time to assess risks, we need to sell,\u201d<\/i><i><\/i>or the classic\u00a0<i>\u201cWe focus on goals, not risks\u2026 if something happens, we\u2019ll fix it.\u201d\u00a0<\/i><i><\/i>Needless to say, some of those organizations didn\u2019t survive COVID.<\/p><p class=\"p1\">Although global pandemics have always existed in threat catalogs, they were usually dismissed due to their low likelihood (like the meteor example: if a meteorite hits our organization, the impact is huge, but the probability is low\u2014none of us have anti-meteorite missiles on the roof). Today, pandemics are a standard part of Risk Analyses (RA) and Business Impact Analyses (BIA), with countermeasures in place in case we can\u2019t reach the office for any reason.<\/p><p><b>NIS2: Strengthening Cybersecurity in Critical Sectors<\/b><\/p><p class=\"p1\">To bring some structure to this evolving landscape, the NIS2 Directive (Network and Information Security Directive) came into effect on October 17, 2024. Its goal is to strengthen cybersecurity across the European Union, directly impacting critical sectors such as the pharmaceutical industry.<\/p><p class=\"p1\">This new version expands and improves on the original NIS directive, as recent reality has shown that many organizations in essential sectors still lack basic cybersecurity measures. These include continuous risk management, proper documentation and notification of security incidents, regular vulnerability assessments, and incident response and continuity plans\u2014especially important in the face of increasingly frequent and sophisticated cyberattacks.<\/p><p class=\"p1\">The core idea behind NIS2 is to broaden cybersecurity enforcement to more sectors (from the original 7 under NIS1 to 35 under NIS2), compelling many more organizations to comply with updated security requirements. Antivirus software and regular backups are no longer enough; now it\u2019s about continuous risk management, advanced technical and organizational safeguards, and stricter penalties for non-compliance.<\/p><p class=\"p1\">For the pharmaceutical sector, the directive applies to the entire value chain\u2014from research and development to manufacturing, distribution, and storage. As the sector undergoes rapid\u00a0<a href=\"https:\/\/www.qualipharmagroup.com\/blog\/qloud-qualificates-the-new-digital-qualification-service\/\">digital<\/a>\u00a0transformation through the adoption of technologies like AI and connected production systems, its attack surface grows significantly. This makes the confidentiality, integrity, availability, and traceability of critical data more important than ever.<\/p><p><b>From Obligation to Strategic Opportunity<\/b><\/p><p class=\"p1\">It\u2019s important to understand that NIS2 doesn\u2019t necessarily mean huge tech investments or inflated IT budgets. In reality, it promotes business resilience and efficiency by enforcing what should be seen as common-sense cybersecurity measures that many companies should have implemented years ago.<\/p><p class=\"p1\">This directive shouldn\u2019t be viewed as a burden but as a valuable opportunity to strengthen the resilience of pharmaceutical companies in an increasingly digital and risk-prone world. Cybersecurity is no longer just a technical issue or a cost\u2014it\u2019s a strategic pillar that can make the difference between business continuity and disruption during a crisis.<\/p><p class=\"p1\">Additionally, GxP regulations not only require validation of systems but also qualification of the IT infrastructure that supports them\u2014directly tied to both security and cybersecurity. Beyond being a regulatory requirement, this is an opportunity to enhance security, ensure data integrity compliance, and guarantee business continuity.<\/p><p><b>Qualipharma: Ready for What\u2019s Next<\/b><\/p><p class=\"p1\">At\u00a0<span class=\"s2\"><b>Qualipharma<\/b><\/span>, we\u2019ve been complying for years with the very standards that the NIS2 Directive now formalizes, ensuring resilience and cybersecurity across our operations.<\/p><p class=\"p1\">If you\u2019re not sure whether your organization meets the new requirements, we can help identify gaps, create a solid action plan for compliance, and support your IT infrastructure\u00a0<a href=\"https:\/\/qloud.qualipharmagroup.com\/\">qualification<\/a>.<\/p><p class=\"p4\"><b>Don\u2019t let cybersecurity be a barrier\u2014turn it into your competitive advantage with Qualipharma.<\/b><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>You wouldn\u2019t believe how many times, when trying to conduct a Risk Analysis in an organization, we\u2019ve heard things like: \u201cIf we only think about the bad stuff, we\u2019ll never get anything done,\u201d <\/p>\n","protected":false},"author":1,"featured_media":9726,"comment_status":"open","ping_status":"open","sticky":false,"template":"elementor_theme","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9724","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sin-categoria"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NIS2 and the Challenge of Turning Risk into Opportunity | Qualipharma<\/title>\n<meta name=\"description\" content=\"Learn how the NIS2 Directive strengthens cybersecurity in pharma. Turn regulatory compliance into opportunity with risk management and\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.qualipharmagroup.com\/en\/blog\/nis2-and-the-challenge-of-turning-risk-into-opportunity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NIS2 and the Challenge of Turning Risk into Opportunity | Qualipharma\" \/>\n<meta property=\"og:description\" content=\"Learn how the NIS2 Directive strengthens cybersecurity in pharma. Turn regulatory compliance into opportunity with risk management and\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.qualipharmagroup.com\/en\/blog\/nis2-and-the-challenge-of-turning-risk-into-opportunity\/\" \/>\n<meta property=\"og:site_name\" content=\"Qualipharma\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-06T08:10:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-03T10:05:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.qualipharmagroup.com\/wp-content\/uploads\/2025\/05\/freepik__the-style-is-candid-image-photography-with-natural__28637-1024x585-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"585\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"desarrollo\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@desarrollo\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"desarrollo\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/en\\\/blog\\\/nis2-and-the-challenge-of-turning-risk-into-opportunity\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/en\\\/blog\\\/nis2-and-the-challenge-of-turning-risk-into-opportunity\\\/\"},\"author\":{\"name\":\"desarrollo\",\"@id\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/#\\\/schema\\\/person\\\/6f5f3e5d5f8f0fda5b114ec13b5e0113\"},\"headline\":\"NIS2 and the Challenge of Turning Risk into Opportunity\",\"datePublished\":\"2025-05-06T08:10:25+00:00\",\"dateModified\":\"2025-09-03T10:05:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/en\\\/blog\\\/nis2-and-the-challenge-of-turning-risk-into-opportunity\\\/\"},\"wordCount\":608,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/en\\\/blog\\\/nis2-and-the-challenge-of-turning-risk-into-opportunity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/freepik__the-style-is-candid-image-photography-with-natural__28637-1024x585-1.jpg\",\"articleSection\":[\"Sin categor\u00eda\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.qualipharmagroup.com\\\/en\\\/blog\\\/nis2-and-the-challenge-of-turning-risk-into-opportunity\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/en\\\/blog\\\/nis2-and-the-challenge-of-turning-risk-into-opportunity\\\/\",\"url\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/en\\\/blog\\\/nis2-and-the-challenge-of-turning-risk-into-opportunity\\\/\",\"name\":\"NIS2 and the Challenge of Turning Risk into Opportunity | Qualipharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/en\\\/blog\\\/nis2-and-the-challenge-of-turning-risk-into-opportunity\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/en\\\/blog\\\/nis2-and-the-challenge-of-turning-risk-into-opportunity\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/freepik__the-style-is-candid-image-photography-with-natural__28637-1024x585-1.jpg\",\"datePublished\":\"2025-05-06T08:10:25+00:00\",\"dateModified\":\"2025-09-03T10:05:53+00:00\",\"description\":\"Learn how the NIS2 Directive strengthens cybersecurity in pharma. Turn regulatory compliance into opportunity with risk management and\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/en\\\/blog\\\/nis2-and-the-challenge-of-turning-risk-into-opportunity\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.qualipharmagroup.com\\\/en\\\/blog\\\/nis2-and-the-challenge-of-turning-risk-into-opportunity\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/en\\\/blog\\\/nis2-and-the-challenge-of-turning-risk-into-opportunity\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/freepik__the-style-is-candid-image-photography-with-natural__28637-1024x585-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/freepik__the-style-is-candid-image-photography-with-natural__28637-1024x585-1.jpg\",\"width\":1024,\"height\":585},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/en\\\/blog\\\/nis2-and-the-challenge-of-turning-risk-into-opportunity\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NIS2 and the Challenge of Turning Risk into Opportunity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/#website\",\"url\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/\",\"name\":\"Qualipharma\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/#organization\",\"name\":\"Qualipharma\",\"url\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/logo-qualipharmagroup.png\",\"contentUrl\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/logo-qualipharmagroup.png\",\"width\":220,\"height\":98,\"caption\":\"Qualipharma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/qualipharma\\\/?viewAsMember=true\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/#\\\/schema\\\/person\\\/6f5f3e5d5f8f0fda5b114ec13b5e0113\",\"name\":\"desarrollo\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b9308274c5556caa1006d5f0eb5451a902f2bf5bc8787eee60c7ef88f57e32e4?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b9308274c5556caa1006d5f0eb5451a902f2bf5bc8787eee60c7ef88f57e32e4?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b9308274c5556caa1006d5f0eb5451a902f2bf5bc8787eee60c7ef88f57e32e4?s=96&d=mm&r=g\",\"caption\":\"desarrollo\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/desarrollo\"],\"url\":\"https:\\\/\\\/www.qualipharmagroup.com\\\/en\\\/blog\\\/author\\\/desarrollo\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NIS2 and the Challenge of Turning Risk into Opportunity | Qualipharma","description":"Learn how the NIS2 Directive strengthens cybersecurity in pharma. Turn regulatory compliance into opportunity with risk management and","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.qualipharmagroup.com\/en\/blog\/nis2-and-the-challenge-of-turning-risk-into-opportunity\/","og_locale":"en_US","og_type":"article","og_title":"NIS2 and the Challenge of Turning Risk into Opportunity | Qualipharma","og_description":"Learn how the NIS2 Directive strengthens cybersecurity in pharma. Turn regulatory compliance into opportunity with risk management and","og_url":"https:\/\/www.qualipharmagroup.com\/en\/blog\/nis2-and-the-challenge-of-turning-risk-into-opportunity\/","og_site_name":"Qualipharma","article_published_time":"2025-05-06T08:10:25+00:00","article_modified_time":"2025-09-03T10:05:53+00:00","og_image":[{"width":1024,"height":585,"url":"https:\/\/www.qualipharmagroup.com\/wp-content\/uploads\/2025\/05\/freepik__the-style-is-candid-image-photography-with-natural__28637-1024x585-1.jpg","type":"image\/jpeg"}],"author":"desarrollo","twitter_card":"summary_large_image","twitter_creator":"@desarrollo","twitter_misc":{"Written by":"desarrollo","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.qualipharmagroup.com\/en\/blog\/nis2-and-the-challenge-of-turning-risk-into-opportunity\/#article","isPartOf":{"@id":"https:\/\/www.qualipharmagroup.com\/en\/blog\/nis2-and-the-challenge-of-turning-risk-into-opportunity\/"},"author":{"name":"desarrollo","@id":"https:\/\/www.qualipharmagroup.com\/#\/schema\/person\/6f5f3e5d5f8f0fda5b114ec13b5e0113"},"headline":"NIS2 and the Challenge of Turning Risk into Opportunity","datePublished":"2025-05-06T08:10:25+00:00","dateModified":"2025-09-03T10:05:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.qualipharmagroup.com\/en\/blog\/nis2-and-the-challenge-of-turning-risk-into-opportunity\/"},"wordCount":608,"commentCount":0,"publisher":{"@id":"https:\/\/www.qualipharmagroup.com\/#organization"},"image":{"@id":"https:\/\/www.qualipharmagroup.com\/en\/blog\/nis2-and-the-challenge-of-turning-risk-into-opportunity\/#primaryimage"},"thumbnailUrl":"https:\/\/www.qualipharmagroup.com\/wp-content\/uploads\/2025\/05\/freepik__the-style-is-candid-image-photography-with-natural__28637-1024x585-1.jpg","articleSection":["Sin categor\u00eda"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.qualipharmagroup.com\/en\/blog\/nis2-and-the-challenge-of-turning-risk-into-opportunity\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.qualipharmagroup.com\/en\/blog\/nis2-and-the-challenge-of-turning-risk-into-opportunity\/","url":"https:\/\/www.qualipharmagroup.com\/en\/blog\/nis2-and-the-challenge-of-turning-risk-into-opportunity\/","name":"NIS2 and the Challenge of Turning Risk into Opportunity | Qualipharma","isPartOf":{"@id":"https:\/\/www.qualipharmagroup.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.qualipharmagroup.com\/en\/blog\/nis2-and-the-challenge-of-turning-risk-into-opportunity\/#primaryimage"},"image":{"@id":"https:\/\/www.qualipharmagroup.com\/en\/blog\/nis2-and-the-challenge-of-turning-risk-into-opportunity\/#primaryimage"},"thumbnailUrl":"https:\/\/www.qualipharmagroup.com\/wp-content\/uploads\/2025\/05\/freepik__the-style-is-candid-image-photography-with-natural__28637-1024x585-1.jpg","datePublished":"2025-05-06T08:10:25+00:00","dateModified":"2025-09-03T10:05:53+00:00","description":"Learn how the NIS2 Directive strengthens cybersecurity in pharma. Turn regulatory compliance into opportunity with risk management and","breadcrumb":{"@id":"https:\/\/www.qualipharmagroup.com\/en\/blog\/nis2-and-the-challenge-of-turning-risk-into-opportunity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.qualipharmagroup.com\/en\/blog\/nis2-and-the-challenge-of-turning-risk-into-opportunity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.qualipharmagroup.com\/en\/blog\/nis2-and-the-challenge-of-turning-risk-into-opportunity\/#primaryimage","url":"https:\/\/www.qualipharmagroup.com\/wp-content\/uploads\/2025\/05\/freepik__the-style-is-candid-image-photography-with-natural__28637-1024x585-1.jpg","contentUrl":"https:\/\/www.qualipharmagroup.com\/wp-content\/uploads\/2025\/05\/freepik__the-style-is-candid-image-photography-with-natural__28637-1024x585-1.jpg","width":1024,"height":585},{"@type":"BreadcrumbList","@id":"https:\/\/www.qualipharmagroup.com\/en\/blog\/nis2-and-the-challenge-of-turning-risk-into-opportunity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/www.qualipharmagroup.com\/en\/"},{"@type":"ListItem","position":2,"name":"NIS2 and the Challenge of Turning Risk into Opportunity"}]},{"@type":"WebSite","@id":"https:\/\/www.qualipharmagroup.com\/#website","url":"https:\/\/www.qualipharmagroup.com\/","name":"Qualipharma","description":"","publisher":{"@id":"https:\/\/www.qualipharmagroup.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.qualipharmagroup.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.qualipharmagroup.com\/#organization","name":"Qualipharma","url":"https:\/\/www.qualipharmagroup.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.qualipharmagroup.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.qualipharmagroup.com\/wp-content\/uploads\/2023\/12\/logo-qualipharmagroup.png","contentUrl":"https:\/\/www.qualipharmagroup.com\/wp-content\/uploads\/2023\/12\/logo-qualipharmagroup.png","width":220,"height":98,"caption":"Qualipharma"},"image":{"@id":"https:\/\/www.qualipharmagroup.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/qualipharma\/?viewAsMember=true"]},{"@type":"Person","@id":"https:\/\/www.qualipharmagroup.com\/#\/schema\/person\/6f5f3e5d5f8f0fda5b114ec13b5e0113","name":"desarrollo","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b9308274c5556caa1006d5f0eb5451a902f2bf5bc8787eee60c7ef88f57e32e4?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b9308274c5556caa1006d5f0eb5451a902f2bf5bc8787eee60c7ef88f57e32e4?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b9308274c5556caa1006d5f0eb5451a902f2bf5bc8787eee60c7ef88f57e32e4?s=96&d=mm&r=g","caption":"desarrollo"},"sameAs":["https:\/\/x.com\/desarrollo"],"url":"https:\/\/www.qualipharmagroup.com\/en\/blog\/author\/desarrollo\/"}]}},"_links":{"self":[{"href":"https:\/\/www.qualipharmagroup.com\/en\/wp-json\/wp\/v2\/posts\/9724","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.qualipharmagroup.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.qualipharmagroup.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.qualipharmagroup.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.qualipharmagroup.com\/en\/wp-json\/wp\/v2\/comments?post=9724"}],"version-history":[{"count":6,"href":"https:\/\/www.qualipharmagroup.com\/en\/wp-json\/wp\/v2\/posts\/9724\/revisions"}],"predecessor-version":[{"id":9838,"href":"https:\/\/www.qualipharmagroup.com\/en\/wp-json\/wp\/v2\/posts\/9724\/revisions\/9838"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.qualipharmagroup.com\/en\/wp-json\/wp\/v2\/media\/9726"}],"wp:attachment":[{"href":"https:\/\/www.qualipharmagroup.com\/en\/wp-json\/wp\/v2\/media?parent=9724"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.qualipharmagroup.com\/en\/wp-json\/wp\/v2\/categories?post=9724"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.qualipharmagroup.com\/en\/wp-json\/wp\/v2\/tags?post=9724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}